

## Table of Contents

|   |           |
|---|-----------|
| <b>ANALYSIS OF ICD-9 PROCEDURE DATA .....</b>   | <b>3</b>  |
| METHODOLOGY .....   | 3         |
| DATA SOURCE AND LIMITATIONS .....   | 3         |
| <b>SUMMARY OF 2005 INPATIENT INTERVENTIONAL MARKET BY TYPE OF PROCEDURE AND VASCULAR TERRITORY .....</b>      | <b>4</b>  |
| INPATIENT LOWER LIMB PROCEDURES .....   | 7         |
| <b>REVASCULARIZATION PROCEDURES SUITABLE FOR TREATMENT WITH PERIOPERATIVE ORAL ANTIPLATELET THERAPY .....</b> | <b>8</b>  |
| AORTOILIAC OR PELVIC DISEASE.....   | 8         |
| <i>Disease Characteristics</i> .....  | 8         |
| <i>Procedures</i> .....   | 8         |
| ABOVE KNEE—FEMOROPOPLITEAL DISEASE .....  | 10        |
| <i>Disease Characteristics</i> .....  | 10        |
| <i>Procedures</i> .....   | 10        |
| BELOW KNEE—TIBIAL AND PERONEAL DISEASE .....  | 12        |
| <i>Disease Characteristics</i> .....  | 12        |
| <i>Procedures</i> .....   | 13        |
| <b>AMPUTATION.....</b>  | <b>15</b> |
| <b>ANALYSIS OF STENTING IN THE LOWER LIMBS .....</b>  | <b>16</b> |
| <b>ESTIMATED OUTPATIENT ENDOVASCULAR PROCEDURES 2005.....</b>   | <b>17</b> |
| METHOD AND ASSUMPTIONS .....  | 17        |
| INPATIENT AND OUTPATIENT ENDOVASCULAR PROCEDURES BY VASCULAR TERRITORY .....                                  | 17        |
| <b>SUMMARY OF INPATIENT AND OUTPATIENT ENDOVASCULAR MARKET.....</b>   | <b>20</b> |
| <b>U.S. PAD PROJECTIONS 2000-2020 .....</b>   | <b>22</b> |
| <b>MARKET POTENTIAL FOR REVASCULARIZATION PROCEDURES .....</b>  | <b>23</b> |
| ASSUMPTIONS EMPLOYED TO CALCULATE MARKET POTENTIAL.....   | 23        |
| ENDOVASCULAR TO GAIN SHARE OF REVASCULARIZATION MARKET .....  | 24        |
| <b>REVASCULARIZATION PROCEDURES 2003-2020 .....</b>   | <b>26</b> |
| U.S. PAD MARKET POTENTIAL FOR REVASCULARIZATION.....  | 26        |
| <b>ENDOVASCULAR MARKET ANALYSIS BY VASCULAR TERRITORY 2000-2020 .....</b>                                     | <b>27</b> |
| ASSUMPTIONS .....   | 27        |
| PERCENTAGE OF PATIENTS REVASCULARIZED REMAINS CONSTANT .....  | 27        |
| PERCENTAGE OF PATIENTS DIAGNOSED AND TREATED EXPECTED TO INCREASE .....                                       | 28        |
| <i>Reflects Technological Innovation and Growing Knowledge and Awareness of PAD</i> .....                     | 28        |
| BELOW KNEE ANGIOPLASTY/ATHERECTOMY PROCEDURES TO EXPAND FASTER THAN THOSE IN OTHER VASCULAR TERRITORIES.....  | 28        |

|  |           |
|--|-----------|
| ENDOVASCULAR PATIENTS TREATED WITH ANGIOPLASTY/ATHERECTOMY OR PRIMARY STENTS .....         | 29        |
| <b>FUTURE ROLE OF PRIMARY STENTING .....</b>   | <b>29</b> |
| AORTOILIAC PRIMARY STENTING PROJECTED TO CONTINUE SHARE GAINS .....                        | 29        |
| INFRAINGUINAL PRIMARY STENTING: TWO ALTERNATIVE SCENARIOS .....                            | 29        |
| <b>INFRAINGUINAL PRIMARY STENTING GAINS SHARE .....</b>                                    | <b>30</b> |
| <b>INFRAINGUINAL PRIMARY STENTING DECLINES .....</b>                                       | <b>30</b> |
| <b>AORTOILIAC ENDOVASCULAR PROCEDURES 2003-2020.....</b>                                   | <b>32</b> |
| PRIMARY STENTING GAINS SHARE RAPIDLY .....   | 32        |
| PRIMARY STENTING GAINS SHARE MODERATELY .....  | 33        |
| <b>ABOVE KNEE ENDOVASCULAR PROCEDURES 2003-2020 .....</b>                                  | <b>35</b> |
| PRIMARY STENTING INCREASES.....  | 35        |
| PRIMARY STENTING DECLINES .....  | 36        |
| <b>BELOW KNEE ENDOVASCULAR PROCEDURES 2003-2020 .....</b>                                  | <b>38</b> |
| PRIMARY STENTING INCREASES.....  | 38        |
| PRIMARY STENTING DECLINES .....  | 39        |
| <b>DISCUSSION OF PREVIOUS ENDOVASCULAR PROJECTIONS BY VASCULAR TERRITORY .....</b>         | <b>41</b> |
| <b>DOLLAR VALUE OF THE PAD ENDOVASCULAR MARKET .....</b>                                   | <b>42</b> |
| <b>APPENDIX A .....</b>  | <b>44</b> |
| HEALTHCARE COST AND UTILIZATION PROJECT.....   | 44        |
| <b>APPENDIX B .....</b>  | <b>45</b> |
| INPATIENT ENDOVASCULAR PROCEDURE ANALYSIS INCLUDING PROVISIONAL STENTS.....                | 45        |
| <b>APPENDIX C .....</b>  | <b>49</b> |
| INTERVENTIONAL PROCEDURES THAT MIGHT REQUIRE PERIOPERATIVE ORAL ANTIPLATELET THERAPY ..... | 49        |
| <b>REFERENCES.....</b>   | <b>50</b> |
| <b>INDEX OF TABLES .....</b>   | <b>55</b> |
| <b>INDEX OF FIGURES .....</b>  | <b>57</b> |
| <b>DISCLOSURE STATEMENT .....</b>  | <b>58</b> |
| STOCK OWNERSHIP.....   | 58        |
| <b>CONTACT INFORMATION.....</b>  | <b>59</b> |